Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Deal Watch: Boehringer, Epizyme Team Up To Develop Epigenetic Cancer Therapies

Executive Summary

BI and Epizyme’s collaboration will focus on developing novel cancer drugs targeting helicase and HAT enzyme dysregulation. MorphoSys and I-Mab will partner on developing an IO therapy targeting C5aR.

Advertisement

Related Content

Leo Lines Up PellePharm Buy In Rare Skin Cancer Deal
Kolon Bounces Back From Failed Japan Invossa Deal With Bigger Mundipharma Alliance
Immunocore Expands IO Pact With Genentech To Target MAGE-A Antigens
Arena To Advance GI, Derm Ambitions With $800m From United For PAH Candidate
Mylan/Theravance’s Yupelri Will Launch Late This Year To Address COPD Niche
Deal Watch: Astellas/Cytokinetics Extend Partnership, Make Progress On SMA Candidate
MaxCyte CEO Says FDA OK Of IND For Its CAR Receptor Candidate Major Milestone
ThromboGenics Eyes Name Change To Oxurion
GSK’s Head Of Artificial Intelligence Unveils R&D Goals
J&J's First-In-Class Tremfya Poised To Join A Crowded Psoriasis Market

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC124196

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel